Tiansheng Pharmaceutical Group Co Ltd Cash Flow Conversion Efficiency
Tiansheng Pharmaceutical Group Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Tiansheng Pharmaceutical Group Co Ltd (002872) has a cash flow conversion efficiency ratio of -0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-22.57 Million ≈ $-3.30 Million USD) by net assets (CN¥1.97 Billion ≈ $288.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tiansheng Pharmaceutical Group Co Ltd (2012–2024)
Cash flow conversion efficiency of Tiansheng Pharmaceutical Group Co Ltd from 2012 to 2024. This chart illustrates how Tiansheng Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Tiansheng Pharmaceutical Group Co Ltd stock price today for real-time trading data and today's change.
Tiansheng Pharmaceutical Group Co Ltd Cash Flow Conversion Ratio Explained
Tiansheng Pharmaceutical Group Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tiansheng Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tiansheng Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency. Also see Tiansheng Pharmaceutical Group Co Ltd stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hudaco
JSE:HDC
|
0.199x |
|
Qinhuangdao Port Co Ltd
F:QHD
|
0.040x |
|
Fortune Ng Fung Food Hebei Co Ltd
SHG:600965
|
0.016x |
|
Hydratec Industries NV
AS:HYDRA
|
0.172x |
|
Ribbon Communications Inc
NASDAQ:RBBN
|
-0.029x |
|
Teraplast Bist
RO:TRP
|
0.028x |
|
First Community Corporation
NASDAQ:FCCO
|
0.057x |
|
NI Holdings Inc
NASDAQ:NODK
|
-0.184x |
Annual Cash Flow Conversion Efficiency for Tiansheng Pharmaceutical Group Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Tiansheng Pharmaceutical Group Co Ltd from 2012 to 2024. Review Tiansheng Pharmaceutical Group Co Ltd (002872) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.01 Billion ≈ $294.76 Million |
CN¥50.15 Million ≈ $7.34 Million |
0.025x | +312.41% |
| 2023-12-31 | CN¥2.10 Billion ≈ $306.66 Million |
CN¥-24.56 Million ≈ $-3.59 Million |
-0.012x | -128.75% |
| 2022-12-31 | CN¥2.19 Billion ≈ $320.11 Million |
CN¥89.18 Million ≈ $13.05 Million |
0.041x | +389.79% |
| 2021-12-31 | CN¥2.28 Billion ≈ $333.52 Million |
CN¥18.97 Million ≈ $2.78 Million |
0.008x | -89.52% |
| 2020-12-31 | CN¥2.39 Billion ≈ $349.69 Million |
CN¥189.75 Million ≈ $27.77 Million |
0.079x | +62.67% |
| 2019-12-31 | CN¥2.95 Billion ≈ $432.30 Million |
CN¥144.21 Million ≈ $21.10 Million |
0.049x | +0.86% |
| 2018-12-31 | CN¥3.18 Billion ≈ $465.60 Million |
CN¥153.99 Million ≈ $22.53 Million |
0.048x | +376.86% |
| 2017-12-31 | CN¥3.19 Billion ≈ $466.69 Million |
CN¥-55.75 Million ≈ $-8.16 Million |
-0.017x | -106.41% |
| 2016-12-31 | CN¥1.86 Billion ≈ $272.02 Million |
CN¥506.68 Million ≈ $74.14 Million |
0.273x | +107.92% |
| 2015-12-31 | CN¥1.63 Billion ≈ $238.37 Million |
CN¥213.54 Million ≈ $31.25 Million |
0.131x | -2.29% |
| 2014-12-31 | CN¥1.43 Billion ≈ $209.40 Million |
CN¥191.99 Million ≈ $28.09 Million |
0.134x | +153.41% |
| 2013-12-31 | CN¥1.08 Billion ≈ $157.71 Million |
CN¥57.06 Million ≈ $8.35 Million |
0.053x | -65.27% |
| 2012-12-31 | CN¥951.66 Million ≈ $139.26 Million |
CN¥145.06 Million ≈ $21.23 Million |
0.152x | -- |
About Tiansheng Pharmaceutical Group Co Ltd
Tiansheng Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and circulation activities. It offers products in various categories, including respiratory, cardiovascular and cerebrovascular, urinary system, gynecological, orthopedic, cardiology, diabetes, anesthetic, and others. It also provides traditional Chinese medicines and glucose injection. The company was founded in… Read more